Mineralys Therapeutics, Common Stock Today
| MLYS Stock | 16.78 0.61 3.77% |
PerformanceModest
| Odds Of DistressLow
|
Mineralys Therapeutics, is selling for under 16.78 as of the 25th of March 2025; that is 3.77 percent up since the beginning of the trading day. The stock's lowest day price was 16.28. Mineralys Therapeutics, has less than a 18 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of February 2023 | Category Healthcare | Classification Health Care |
Mineralys Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 62.8 M outstanding shares of which 1.75 M shares are now shorted by private and institutional investors with about 5.94 trading days to cover. More on Mineralys Therapeutics, Common
Moving against Mineralys Stock
Mineralys Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Jon Congleton | |||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsMineralys Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mineralys Therapeutics,'s financial leverage. It provides some insight into what part of Mineralys Therapeutics,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Mineralys Therapeutics, Common (MLYS) is traded on NASDAQ Exchange in USA. It is located in 150 N. Radnor Chester Rd., Radnor, PA, United States, 19087 and employs 51 people. Mineralys Therapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.02 B. Mineralys Therapeutics, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 62.8 M outstanding shares of which 1.75 M shares are now shorted by private and institutional investors with about 5.94 trading days to cover.
Mineralys Therapeutics, generates negative cash flow from operations
Check Mineralys Therapeutics, Probability Of Bankruptcy
Ownership AllocationMineralys Therapeutics, maintains a total of 62.8 Million outstanding shares. The majority of Mineralys Therapeutics, outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mineralys Therapeutics, Common to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mineralys Therapeutics,. Please pay attention to any change in the institutional holdings of Mineralys Therapeutics, as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mineralys Ownership Details
Mineralys Therapeutics, Historical Income Statement
Mineralys Stock Against Markets
Mineralys Therapeutics, Corporate Management
| Robert McKean | Senior CMC | Profile | |
| Sarah Foster | Vice Resources | Profile | |
| Danielle Bradbury | Senior Assurance | Profile | |
| Cindy Berejikian | Executive Operations | Profile | |
| Minji MBA | Chief Officer | Profile |
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.